Details of the Drug

General Information of Drug (ID: DMHYLQ2)

Drug Name

Lithium chloride

Synonyms

LITHIUM CHLORIDE; 7447-41-8; Lithiumchloride; Lithium chloride (LiCl); LiCl; chlorure de lithium; Chlorku litu; chlorolithium; Lithiumchlorid; Chlorku litu [Polish]; Luthium chloride; Chlorure de lithium [French]; CCRIS 5924; UNII-G4962QA067; HSDB 4281; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; CHEMBL69710; CHEBI:48607; NSC327172; MFCD00011078; G4962QA067; Lithium chloride, 99%, extra pure; ClLi; Lithium chloride, 99+%, ACS reagent; Lithium chloride, 99%, for molecular biology; Lithium chloride, 99%, for analysis, anhyd

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

42.4

Topological Polar Surface Area

Not Available

Rotatable Bond Count

0

Hydrogen Bond Donor Count

0

Hydrogen Bond Acceptor Count

1

Chemical Identifiers

Formula: ClLi
IUPAC Name: lithium;chloride
Canonical SMILES: [Li+].[Cl-]
InChI: InChI=1S/ClH.Li/h1H;/q;+1/p-1
InChIKey: KWGKDLIKAYFUFQ-UHFFFAOYSA-M

Cross-matching ID

PubChem CID: 433294
ChEBI ID: CHEBI:48607
CAS Number: 7447-41-8
DrugBank ID: DB16607
TTD ID: D07WXT

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen synthase kinase-3 alpha (GSK-3A)	TTRZQE3	GSK3A_HUMAN	Inhibitor	[1], [2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
2	Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 2002 Mar;8(3):126-32.
3	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
4	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
5	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.